Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Structural determinants and genetic modifications enhance BMP2 stability and extracellular secretion.

Khattar V, Lee JH, Wang H, Bastola S, Ponnazhagan S.

FASEB Bioadv. 2019 Mar;1(3):180-190. doi: 10.1096/fba.2018-00023. Epub 2018 Nov 14.

PMID:
31225515
2.

Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity.

Hensel JA, Khattar V, Ashton R, Ponnazhagan S.

Mol Ther Oncolytics. 2018 Dec 13;12:41-48. doi: 10.1016/j.omto.2018.12.004. eCollection 2019 Mar 29.

3.

Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations.

Hensel JA, Khattar V, Ashton R, Ponnazhagan S.

Lab Invest. 2019 Jan;99(1):93-106. doi: 10.1038/s41374-018-0137-1. Epub 2018 Oct 23.

4.

Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus.

Urbanska AM, Ponnazhagan S, Mozafari M.

Cancer Res. 2018 Jul 15;78(14):3747-3754. doi: 10.1158/0008-5472.CAN-18-0206. Epub 2018 Jun 29. Review.

5.

Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.

Wang Y, Schafer CC, Hough KP, Tousif S, Duncan SR, Kearney JF, Ponnazhagan S, Hsu HC, Deshane JS.

J Immunol. 2018 Jul 1;201(1):278-295. doi: 10.4049/jimmunol.1701069. Epub 2018 May 11.

6.

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.

Higgs JT, Lee JH, Wang H, Ramani VC, Chanda D, Hardy CY, Sanderson RD, Ponnazhagan S.

Blood Adv. 2017 Nov 21;1(25):2375-2385. doi: 10.1182/bloodadvances.2017007310. eCollection 2017 Nov 28.

7.

Effects of Cellular Methylation on Transgene Expression and Site-Specific Integration of Adeno-Associated Virus.

Chanda D, Hensel JA, Higgs JT, Grover R, Kaza N, Ponnazhagan S.

Genes (Basel). 2017 Sep 18;8(9). pii: E232. doi: 10.3390/genes8090232.

8.

Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment.

Moore-Smith LD, Isayeva T, Lee JH, Frost A, Ponnazhagan S.

Sci Rep. 2017 Aug 17;7(1):8678. doi: 10.1038/s41598-017-09062-y.

9.

Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity.

McConnell M, Feng S, Chen W, Zhu G, Shen D, Ponnazhagan S, Deng L, Li YP.

Oncotarget. 2017 Jul 18;8(29):47675-47690. doi: 10.18632/oncotarget.17544.

10.

Location of tumor affects local and distant immune cell type and number.

Hensel JA, Khattar V, Ashton R, Lee C, Siegal GP, Ponnazhagan S.

Immun Inflamm Dis. 2017 Feb 23;5(1):85-94. doi: 10.1002/iid3.144. eCollection 2017 Mar.

11.

Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells.

Kumar S, Eroglu E, Stokes JA 3rd, Scissum-Gunn K, Saldanha SN, Singh UP, Manne U, Ponnazhagan S, Mishra MK.

Oncotarget. 2017 Mar 28;8(13):20895-20908. doi: 10.18632/oncotarget.14947.

12.

Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress.

Lee JH, Kang M, Wang H, Naik G, Mobley JA, Sonpavde G, Garvey WT, Darley-Usmar VM, Ponnazhagan S.

FASEB J. 2017 Apr;31(4):1608-1619. doi: 10.1096/fj.201601178R. Epub 2017 Jan 9.

13.

Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade.

Levy S, Feduska JM, Sawant A, Gilbert SR, Hensel JA, Ponnazhagan S.

Bone. 2016 Dec;93:113-124. doi: 10.1016/j.bone.2016.09.018. Epub 2016 Sep 21.

14.

Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.

Schafer CC, Wang Y, Hough KP, Sawant A, Grant SC, Thannickal VJ, Zmijewski J, Ponnazhagan S, Deshane JS.

Oncotarget. 2016 Nov 15;7(46):75407-75424. doi: 10.18632/oncotarget.12249.

15.

Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages.

Cha HR, Lee JH, Hensel JA, Sawant AB, Davis BH, Lee CM, Deshane JS, Ponnazhagan S.

Prostate. 2016 May;76(7):624-36. doi: 10.1002/pros.23155. Epub 2016 Feb 9.

16.

SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells.

Yu H, Liu Y, McFarland BC, Deshane JS, Hurst DR, Ponnazhagan S, Benveniste EN, Qin H.

Cancer Immunol Res. 2015 Jul;3(7):727-40. doi: 10.1158/2326-6066.CIR-15-0004. Epub 2015 Feb 3.

17.

Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.

Higgs JT, Jarboe JS, Lee JH, Chanda D, Lee CM, Deivanayagam C, Ponnazhagan S.

Mol Cancer Res. 2015 May;13(5):819-27. doi: 10.1158/1541-7786.MCR-14-0492. Epub 2015 Jan 30.

18.

Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and correlation with prognosis.

Andea AA, Patel R, Ponnazhagan S, Isayeva T, Kumar S, Siegal GP.

Rom J Morphol Embryol. 2014;55(3 Suppl):1057-62.

19.

Endostatin: A novel inhibitor of androgen receptor function in prostate cancer.

Lee JH, Isayeva T, Larson MR, Sawant A, Cha HR, Chanda D, Chesnokov IN, Ponnazhagan S.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1392-7. doi: 10.1073/pnas.1417660112. Epub 2015 Jan 20.

20.
21.

Anterior gradient protein-2 is a regulator of cellular adhesion in prostate cancer.

Chanda D, Lee JH, Sawant A, Hensel JA, Isayeva T, Reilly SD, Siegal GP, Smith C, Grizzle W, Singh R, Ponnazhagan S.

PLoS One. 2014 Feb 27;9(2):e89940. doi: 10.1371/journal.pone.0089940. eCollection 2014.

22.

Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.

Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC, Ponnazhagan S, Deshane JS.

Cancer Res. 2013 Nov 15;73(22):6609-20. doi: 10.1158/0008-5472.CAN-13-0987. Epub 2013 Oct 1.

23.

Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis.

Sawant A, Ponnazhagan S.

Cancer Res. 2013 Aug 1;73(15):4606-10. doi: 10.1158/0008-5472.CAN-13-0305. Epub 2013 Jul 25. Review.

24.
25.

Role of plasmacytoid dendritic cells in breast cancer bone dissemination.

Sawant A, Ponnazhagan S.

Oncoimmunology. 2013 Feb 1;2(2):e22983.

26.

Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.

Sawant A, Deshane J, Jules J, Lee CM, Harris BA, Feng X, Ponnazhagan S.

Cancer Res. 2013 Jan 15;73(2):672-82. doi: 10.1158/0008-5472.CAN-12-2202. Epub 2012 Dec 14.

27.

Polyglutamate directed coupling of bioactive peptides for the delivery of osteoinductive signals on allograft bone.

Culpepper BK, Bonvallet PP, Reddy MS, Ponnazhagan S, Bellis SL.

Biomaterials. 2013 Feb;34(5):1506-13. doi: 10.1016/j.biomaterials.2012.10.046. Epub 2012 Nov 23.

28.

Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells.

Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A, Ponnazhagan S.

J Immunol. 2012 Nov 1;189(9):4258-65. doi: 10.4049/jimmunol.1101855. Epub 2012 Sep 26.

29.

Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model.

Yang J, Pattanayak A, Song M, Kou J, Taguchi H, Paul S, Ponnazhagan S, Lalonde R, Fukuchi K.

J Mol Neurosci. 2013 Feb;49(2):277-88. doi: 10.1007/s12031-012-9877-3. Epub 2012 Sep 4.

30.

Noggin is novel inducer of mesenchymal stem cell adipogenesis: implications for bone health and obesity.

Sawant A, Chanda D, Isayeva T, Tsuladze G, Garvey WT, Ponnazhagan S.

J Biol Chem. 2012 Apr 6;287(15):12241-9. doi: 10.1074/jbc.M111.293613. Epub 2012 Feb 20.

31.

Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect.

Kumar S, Ponnazhagan S.

Bone. 2012 Apr;50(4):1012-8. doi: 10.1016/j.bone.2012.01.027. Epub 2012 Feb 9.

32.

Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice.

Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y.

Cancer Immunol Immunother. 2012 Sep;61(9):1441-50. doi: 10.1007/s00262-012-1204-x. Epub 2012 Feb 5.

PMID:
22310929
33.

Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer.

Yang SW, Chanda D, Cody JJ, Rivera AA, Waehler R, Siegal GP, Douglas JT, Ponnazhagan S.

PLoS One. 2011;6(10):e25131. doi: 10.1371/journal.pone.0025131. Epub 2011 Oct 12.

34.

Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.

Triozzi PL, Aldrich W, Ponnazhagan S.

Cancer Gene Ther. 2011 Dec;18(12):850-8. doi: 10.1038/cgt.2011.54. Epub 2011 Aug 26.

35.

Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model.

Kou J, Kim H, Pattanayak A, Song M, Lim JE, Taguchi H, Paul S, Cirrito JR, Ponnazhagan S, Fukuchi K.

J Alzheimers Dis. 2011;27(1):23-38. doi: 10.3233/JAD-2011-110230.

36.

Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.

Yang SW, Cody JJ, Rivera AA, Waehler R, Wang M, Kimball KJ, Alvarez RA, Siegal GP, Douglas JT, Ponnazhagan S.

Clin Cancer Res. 2011 Feb 1;17(3):538-49. doi: 10.1158/1078-0432.CCR-10-1628. Epub 2010 Nov 29.

37.

LL-37 as a therapeutic target for late stage prostate cancer.

Hensel JA, Chanda D, Kumar S, Sawant A, Grizzle WE, Siegal GP, Ponnazhagan S.

Prostate. 2011 May;71(6):659-70. doi: 10.1002/pros.21282. Epub 2010 Oct 18.

38.

Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.

Triozzi PL, Aldrich W, Ponnazhagan S.

Vaccine. 2010 Nov 23;28(50):7837-43. doi: 10.1016/j.vaccine.2010.09.086. Epub 2010 Oct 27.

PMID:
20937315
39.

Bacteriophage hyaluronidase effectively inhibits growth, migration and invasion by disrupting hyaluronan-mediated Erk1/2 activation and RhoA expression in human breast carcinoma cells.

Lee JH, Moore LD, Kumar S, Pritchard DG, Ponnazhagan S, Deivanayagam C.

Cancer Lett. 2010 Dec 8;298(2):238-49. doi: 10.1016/j.canlet.2010.07.011. Epub 2010 Aug 4.

PMID:
20688428
40.

Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status.

Andea AA, Patel R, Ponnazhagan S, Kumar S, DeVilliers P, Jhala D, Eltoum IE, Siegal GP.

Hum Pathol. 2010 Oct;41(10):1405-12. doi: 10.1016/j.humpath.2010.02.010. Epub 2010 Jul 1.

41.

Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.

Chanda D, Kumar S, Ponnazhagan S.

J Cell Biochem. 2010 Oct 1;111(2):249-57. doi: 10.1002/jcb.22701. Review.

42.

Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect.

Kumar S, Wan C, Ramaswamy G, Clemens TL, Ponnazhagan S.

Mol Ther. 2010 May;18(5):1026-34. doi: 10.1038/mt.2009.315. Epub 2010 Jan 12.

43.

Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis.

Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, Siegal GP, Beatty MS, Ponnazhagan S.

Clin Cancer Res. 2009 Dec 1;15(23):7175-85. doi: 10.1158/1078-0432.CCR-09-1938. Epub 2009 Nov 17.

44.

Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4.

Byon CH, Hardy RW, Ren C, Ponnazhagan S, Welch DR, McDonald JM, Chen Y.

Lab Invest. 2009 Nov;89(11):1221-8. doi: 10.1038/labinvest.2009.97. Epub 2009 Sep 14.

45.

Therapeutic potential of genetically modified adult stem cells for osteopenia.

Kumar S, Nagy TR, Ponnazhagan S.

Gene Ther. 2010 Jan;17(1):105-16. doi: 10.1038/gt.2009.116. Epub 2009 Sep 10.

46.

High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1.

Westbrook L, Ramanathan HN, Isayeva T, Mittal AR, Qu Z, Johnson MD, Kern FG, Ponnazhagan S, Grubbs CJ, Thottassery JV.

Int J Oncol. 2009 May;34(5):1425-31.

PMID:
19360356
47.

Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status.

Isayeva T, Moore LD, Chanda D, Chen D, Ponnazhagan S.

Prostate. 2009 Jul 1;69(10):1055-66. doi: 10.1002/pros.20952.

48.

Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome.

Zhang J, Luo B, Tang L, Wang Y, Stockard CR, Kadish I, Van Groen T, Grizzle WE, Ponnazhagan S, Fallon MB.

Gastroenterology. 2009 Mar;136(3):1070-80. doi: 10.1053/j.gastro.2008.12.001. Epub 2008 Dec 3.

49.

Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells.

White AF, Mazur M, Sorscher EJ, Zinn KR, Ponnazhagan S.

Hum Gene Ther. 2008 Dec;19(12):1407-14. doi: 10.1089/hgt.2008.117.

50.

Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.

Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG, Gryaznov S, Weaver DW, Goyal RK.

Clin Cancer Res. 2008 Aug 1;14(15):4971-80. doi: 10.1158/1078-0432.CCR-08-0473.

Supplemental Content

Loading ...
Support Center